![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C8H11NO5 |
Molar mass | 201.178 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
HYDIA is a drug that is used in neuroscience research, which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors ( mGluR2/3). It has been useful in the mapping of the group II mGluR receptor proteins and their molecular modeling. [1] HYDIA is similar in structure to group II mGluR agonists such as eglumetad and pomaglumetad, but the addition of the 3-hydroxy group reverses the activity to a competitive antagonist. Other derivatives such as the 3-benzyloxy ether are more potent antagonists than HYDIA itself. [2]
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C8H11NO5 |
Molar mass | 201.178 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
HYDIA is a drug that is used in neuroscience research, which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors ( mGluR2/3). It has been useful in the mapping of the group II mGluR receptor proteins and their molecular modeling. [1] HYDIA is similar in structure to group II mGluR agonists such as eglumetad and pomaglumetad, but the addition of the 3-hydroxy group reverses the activity to a competitive antagonist. Other derivatives such as the 3-benzyloxy ether are more potent antagonists than HYDIA itself. [2]